Pluri Inc.
PLUR$22M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaHAIFA180 employees
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
PLUR News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
No drugs found in this phase.
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply